Log in

NASDAQ:NCNA - NuCana Stock Price, Forecast & News

+0.25 (+4.79 %)
(As of 02/18/2020 02:06 AM ET)
Today's Range
Now: $5.47
50-Day Range
MA: $5.45
52-Week Range
Now: $5.47
Volume14,911 shs
Average Volume40,664 shs
Market Capitalization$176.30 million
P/E RatioN/A
Dividend YieldN/A
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NCNA



Sales & Book Value

Annual SalesN/A
Book Value$3.42 per share


Net Income$-18,470,000.00


Market Cap$176.30 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive NCNA News and Ratings via Email

Sign-up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.

NuCana (NASDAQ:NCNA) Frequently Asked Questions

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

How were NuCana's earnings last quarter?

NuCana PLC (NASDAQ:NCNA) announced its earnings results on Wednesday, November, 13th. The company reported ($12.00) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($22.80) by $10.80. View NuCana's Earnings History.

When is NuCana's next earnings date?

NuCana is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for NuCana.

What price target have analysts set for NCNA?

5 brokerages have issued 1-year price targets for NuCana's shares. Their forecasts range from $15.00 to $25.00. On average, they expect NuCana's share price to reach $19.00 in the next year. This suggests a possible upside of 247.3% from the stock's current price. View Analyst Price Targets for NuCana.

What is the consensus analysts' recommendation for NuCana?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NuCana.

What are Wall Street analysts saying about NuCana stock?

Here are some recent quotes from research analysts about NuCana stock:
  • 1. According to Zacks Investment Research, "NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. " (1/21/2020)
  • 2. HC Wainwright analysts commented, "We have valued NuCana on a discounted cash flow (DCF) basis, which yields a $624M projected enterprise value as of mid-2020. Our calculations rely upon a 60% probability of approval for Acelarin across both front-line BTC and fourth-line 30% probability of approval for NUC-3373 in the mCRC indication. We utilize a 12% discount rate and 17% effective corporate income tax rate, along with a 1% terminal growth rate." (8/19/2019)

Has NuCana been receiving favorable news coverage?

News stories about NCNA stock have been trending extremely negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NuCana earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for NuCana.

Who are some of NuCana's key competitors?

What other stocks do shareholders of NuCana own?

Who are NuCana's key executives?

NuCana's management team includes the folowing people:
  • Prof. Christopher B. Wood, Chairman & Chief Medical Officer (Age 73)
  • Mr. Hugh S. Griffith, Founder, CEO & Director (Age 51)
  • Mr. Donald Munoz, Chief Financial Officer (Age 50)

When did NuCana IPO?

(NCNA) raised $100 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

Who are NuCana's major shareholders?

NuCana's stock is owned by many different of retail and institutional investors. Top institutional investors include Tang Capital Management LLC (0.78%), Asymmetry Capital Management L.P. (0.50%), Renaissance Technologies LLC (0.26%), Marshall Wace LLP (0.20%) and Blair William & Co. IL (0.05%).

Which institutional investors are selling NuCana stock?

NCNA stock was sold by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Blair William & Co. IL and Asymmetry Capital Management L.P..

Which institutional investors are buying NuCana stock?

NCNA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Marshall Wace LLP.

How do I buy shares of NuCana?

Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $5.47.

How big of a company is NuCana?

NuCana has a market capitalization of $176.30 million. The company earns $-18,470,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. NuCana employs 21 workers across the globe.View Additional Information About NuCana.

What is NuCana's official website?

The official website for NuCana is http://www.nucana.com/.

How can I contact NuCana?

NuCana's mailing address is 3 LOCHSIDE WAY, EDINBURGH X0, EH12 9DT. The company can be reached via phone at 44-0-13-1357-1111 or via email at [email protected]

MarketBeat Community Rating for NuCana (NASDAQ NCNA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  408
MarketBeat's community ratings are surveys of what our community members think about NuCana and other stocks. Vote "Outperform" if you believe NCNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel